The Application of NMR-based Metabonomics in Neurological Disorders

Overview

Journal NeuroRx

Specialty Neurology

Date 2006 Jul 4

PMID 16815219

Citations 17

Authors

Elaine Holmes

Tsz M Tsang

Sarah J Tabrizi

Affiliations

Soon will be listed here.

Abstract

Advances in postgenomic technologies have radically changed the information output from complex biological systems, generating vast amounts of high complexity data that can be interpreted by means of chemometric and bioinformatic methods to achieve disease diagnosis and prognosis. High-resolution nuclear magnetic resonance (NMR) spectroscopy of biofluids such as plasma, cerebrospinal fluid (CSF), and urine can generate robust, interpretable metabolic fingerprints that contain latent information relating to physiological or pathological status. This technology has been successfully applied to both preclinical and clinical studies of neurodegenerative diseases such as Huntington's disease, muscular dystrophy, and cerebellar ataxia. An extension of this technology, (1)H magic-angle-spinning (HRMAS) NMR spectroscopy, can be used to generate metabolic information on small intact tissue samples, providing a metabolic link between metabolic profiling of biofluids and histology. In this review we provide a summary of high-resolution NMR studies in neurodegenerative disease and explore the potential of metabonomics in evaluating disease progression with respect to therapeutic intervention.

Citing Articles

NMR-Based Metabolomics of Rat Hippocampus, Serum, and Urine in Two Models of Autism.

Toczylowska B, Zieminska E, Polowy R, Olszynski K, Lazarewicz J Mol Neurobiol. 2022; 59(9):5452-5475.

PMID: 35715683 DOI: 10.1007/s12035-022-02912-5.

Effects of Methylphenidate on the Dopamine Transporter and Beyond.

Zetterstrom T, Quansah E, Grootveld M Curr Top Behav Neurosci. 2022; 57:127-157.

PMID: 35507284 DOI: 10.1007/7854_2022_333.

Untargeted Metabolomic Profiling Using UHPLC-QTOF/MS Reveals Metabolic Alterations Associated with Autism.

Liang Y, Ke X, Xiao Z, Zhang Y, Chen Y, Li Y Biomed Res Int. 2020; 2020:6105608.

PMID: 32964039 PMC: 7502129. DOI: 10.1155/2020/6105608.

Hippocampal Metabolite Profiles in Two Rat Models of Autism: NMR-Based Metabolomics Studies.

Toczylowska B, Zieminska E, Senator P, Lazarewicz J Mol Neurobiol. 2020; 57(7):3089-3105.

PMID: 32468248 PMC: 7320041. DOI: 10.1007/s12035-020-01935-0.

Metabolite Profile of Alzheimer's Disease in the Frontal Cortex as Analyzed by HRMAS H NMR.

Zhang Y, Liu Z, Ji B, Liu L, Wu S, Liu X Front Aging Neurosci. 2019; 10:424.

PMID: 30687076 PMC: 6333733. DOI: 10.3389/fnagi.2018.00424.

References

Yang J, Xu G, Hong Q, Liebich H, Lutz K, Schmulling R . Discrimination of Type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profiles. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 813(1-2):53-8. DOI: 10.1016/j.jchromb.2004.09.023. View

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

Bales J, Higham D, Howe I, Nicholson J, Sadler P . Use of high-resolution proton nuclear magnetic resonance spectroscopy for rapid multi-component analysis of urine. Clin Chem. 1984; 30(3):426-32. View

Brouwer O, Laboyrie P, Peters A, Vielvoye G . Follow-up magnetic resonance imaging in Hallervorden-Spatz disease. Clin Neurol Neurosurg. 1992; 94 Suppl:S57-60. DOI: 10.1016/0303-8467(92)90023-v. View

Chen Y, Galpern W, Brownell A, Matthews R, Bogdanov M, Isacson O . Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn Reson Med. 1997; 38(3):389-98. DOI: 10.1002/mrm.1910380306. View

Nicholson J, Timbrell J, Sadler P . Proton NMR spectra of urine as indicators of renal damage. Mercury-induced nephrotoxicity in rats. Mol Pharmacol. 1985; 27(6):644-51. View

Wang Y, Holmes E, Nicholson J, Cloarec O, Chollet J, Tanner M . Metabonomic investigations in mice infected with Schistosoma mansoni: an approach for biomarker identification. Proc Natl Acad Sci U S A. 2004; 101(34):12676-81. PMC: 515115. DOI: 10.1073/pnas.0404878101. View

Bonifati V, Rizzu P, van Baren M, Schaap O, Breedveld G, Krieger E . Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2002; 299(5604):256-9. DOI: 10.1126/science.1077209. View

Kasparova S, Sumbalova Z, Bystricky P, Kucharska J, Liptaj T, Mlynarik V . Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease. Neurochem Int. 2005; 48(2):93-9. DOI: 10.1016/j.neuint.2005.09.002. View

10.

Sveinbjornsdottir S, Hicks A, Jonsson T, Petursson H, Gugmundsson G, Frigge M . Familial aggregation of Parkinson's disease in Iceland. N Engl J Med. 2000; 343(24):1765-70. DOI: 10.1056/NEJM200012143432404. View

11.

Pears M, Cooper J, Mitchison H, Mortishire-Smith R, Pearce D, Griffin J . High resolution 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease. J Biol Chem. 2005; 280(52):42508-14. DOI: 10.1074/jbc.M507380200. View

12.

Karrenbauer V, Leoni V, Lim E, Giovannoni G, Ingle G, Sastre-Garriga J . Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. Clin Neurol Neurosurg. 2005; 108(5):456-60. DOI: 10.1016/j.clineuro.2005.07.010. View

13.

Griffin J, Cemal C, Pook M . Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3. Physiol Genomics. 2003; 16(3):334-40. DOI: 10.1152/physiolgenomics.00149.2003. View

14.

Holowenko D, Peeling J, Sutherland G . 1H NMR properties of N-acetylaspartylglutamate in extracts of nervous tissue of the rat. NMR Biomed. 1992; 5(1):43-7. DOI: 10.1002/nbm.1940050108. View

15.

Horska A, Naidu S, Herskovits E, Wang P, Kaufmann W, Barker P . Quantitative 1H MR spectroscopic imaging in early Rett syndrome. Neurology. 2000; 54(3):715-22. DOI: 10.1212/wnl.54.3.715. View

16.

Bender A, Auer D, Merl T, Reilmann R, Saemann P, Yassouridis A . Creatine supplementation lowers brain glutamate levels in Huntington's disease. J Neurol. 2005; 252(1):36-41. DOI: 10.1007/s00415-005-0595-4. View

17.

Govindaraju V, Young K, Maudsley A . Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000; 13(3):129-53. DOI: 10.1002/1099-1492(200005)13:3<129::aid-nbm619>3.0.co;2-v. View

18.

Shockcor J, Unger S, Wilson I, Foxall P, Nicholson J, Lindon J . Combined HPLC, NMR spectroscopy, and ion-trap mass spectrometry with application to the detection and characterization of xenobiotic and endogenous metabolites in human urine. Anal Chem. 1996; 68(24):4431-5. DOI: 10.1021/ac9606463. View

19.

Nicholson J, Connelly J, Lindon J, Holmes E . Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov. 2002; 1(2):153-61. DOI: 10.1038/nrd728. View

20.

van Dellen A, Welch J, Dixon R, Cordery P, York D, Styles P . N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Neuroreport. 2000; 11(17):3751-7. DOI: 10.1097/00001756-200011270-00032. View